Huadong Medicine announcement: subsidiary Bohua Pharmaceutical acquires 100% equity of Guizhou Hengba Pharmaceutical Co., Ltd., with a transaction base price of 0.52847 billion yuan and a floating price to be paid according to the agreement.
华东医药：子公司博华制药收购恒霸药业100%股权
Huadong Medicine: Subsidiary Bohua Pharmaceutical acquires 100% equity of Hengba Pharmaceutical.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.